{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:37:27Z","timestamp":1788352647147,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15127-3","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:53:54Z","timestamp":1763772834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of immune checkpoint inhibitors in patients with triple-negative breast cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Xin","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"3","key":"15127_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin."},{"issue":"7","key":"15127_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s12276-023-01030-z","volume":"55","author":"JY Kim","year":"2023","unstructured":"Kim JY, Park S, Cho EY, et al. Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer. Exp Mol Med. 2023;55(7):1451\u201361. https:\/\/doi.org\/10.1038\/s12276-023-01030-z.","journal-title":"Exp Mol Med"},{"issue":"26","key":"15127_CR3","doi-asserted-by":"publisher","first-page":"eadg0289","DOI":"10.1126\/sciadv.adg0289","volume":"9","author":"T Arulraj","year":"2023","unstructured":"Arulraj T, Wang H, Emens LA, et al. A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 Inhibition. Sci Adv. 2023;9(26):eadg0289. https:\/\/doi.org\/10.1126\/sciadv.adg0289.","journal-title":"Sci Adv"},{"issue":"1","key":"15127_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. https:\/\/doi.org\/10.1186\/s13045-022-01341-0.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"15127_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","volume":"35","author":"F Yang","year":"2023","unstructured":"Yang F, Xiao Y, Ding JH, et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2023;35(1):84\u2013e1008. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.021.","journal-title":"Cell Metab"},{"issue":"2","key":"15127_CR6","doi-asserted-by":"publisher","first-page":"188593","DOI":"10.1016\/j.bbcan.2021.188593","volume":"1876","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Zhu X, Tang C, et al. Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188593. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188593.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"15127_CR7","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.4103\/jcrt.jcrt_1867_20","volume":"18","author":"N Mittal","year":"2022","unstructured":"Mittal N, Singh S, Mittal R, et al. Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis. J Cancer Res Ther. 2022;18(6):1754\u201365. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1867_20.","journal-title":"J Cancer Res Ther"},{"key":"15127_CR8","doi-asserted-by":"publisher","first-page":"1137464","DOI":"10.3389\/fendo.2023.1137464","volume":"14","author":"X Liang","year":"2023","unstructured":"Liang X, Chen X, Li H, et al. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2023;14:1137464. https:\/\/doi.org\/10.3389\/fendo.2023.1137464.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"15127_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.20517\/cdr.2023.58","volume":"6","author":"RS Wong","year":"2023","unstructured":"Wong RS, Ong RJ, Lim JS. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies. Cancer Drug Resist. 2023;6(4):768\u201387. https:\/\/doi.org\/10.20517\/cdr.2023.58.","journal-title":"Cancer Drug Resist"},{"issue":"10","key":"15127_CR10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-Related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol. 2016;2(10):1346\u201353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051.","journal-title":"JAMA Oncol"},{"issue":"1","key":"15127_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12916-020-01718-3","volume":"18","author":"F Teng","year":"2020","unstructured":"Teng F, Li M, Yu J. Radiation recall pneumonitis induced by PD-1\/PD-L1 blockades: mechanisms and therapeutic implications. BMC Med. 2020;18(1):275. https:\/\/doi.org\/10.1186\/s12916-020-01718-3.","journal-title":"BMC Med"},{"key":"15127_CR12","doi-asserted-by":"publisher","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint Blockade. N Engl J Med. 2018;378(2):158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481.","DOI":"10.1056\/NEJMra1703481"},{"key":"15127_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"15127_CR14","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377\u201385. https:\/\/doi.org\/10.1093\/annonc\/mdx286.","journal-title":"Ann Oncol"},{"key":"15127_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"key":"15127_CR16","doi-asserted-by":"publisher","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"15127_CR17","doi-asserted-by":"publisher","unstructured":"Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25(6):646\u201354. https:\/\/doi.org\/10.1177\/0272989X05282643.","DOI":"10.1177\/0272989X05282643"},{"key":"15127_CR18","volume-title":"Cochrane handbook for systematic reviews of interventions 5.0.1","author":"JJ Deeks","year":"2008","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions 5.0.1. Oxford, UK: The Cochrane Collaboration; 2008."},{"issue":"7414","key":"15127_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"2","key":"15127_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-analysis: model Estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111\u201325. https:\/\/doi.org\/10.1002\/jrsm.1045.","journal-title":"Res Synth Methods"},{"issue":"6","key":"15127_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391. https:\/\/doi.org\/10.1016\/s0895-4356(97)00049-8.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"15127_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.016.","journal-title":"J Clin Epidemiol"},{"key":"15127_CR23","first-page":"15","volume":"47","author":"A Tobias","year":"1999","unstructured":"Tobias A. Assessing the influence of a single study in the meta-analysis. Stata Tech Bull. 1999;47:15\u20137.","journal-title":"Stata Tech Bull"},{"key":"15127_CR24","doi-asserted-by":"publisher","unstructured":"Riley RD, Debray TPA, Fisher D et al. Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: Statistical recommendations for conduct and planning. Stat Med. 2020;39(15): 2115\u20132137. doi: 10.1002\/sim.8516.Egger M, Davey Smith G, Schneider M, Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u2009\u2013\u200934. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","DOI":"10.1136\/bmj.315.7109.629"},{"issue":"4","key":"15127_CR25","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101.","journal-title":"Biometrics"},{"issue":"22","key":"15127_CR26","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in advanced Triple-Negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","journal-title":"N Engl J Med"},{"issue":"8","key":"15127_CR27","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279\u201388. https:\/\/doi.org\/10.1093\/annonc\/mdz158.","journal-title":"Ann Oncol"},{"issue":"10265","key":"15127_CR28","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9.","journal-title":"Lancet"},{"issue":"10257","key":"15127_CR29","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant Atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090\u2013100. https:\/\/doi.org\/10.1016\/S0140-6736(20)31953-X.","journal-title":"Lancet"},{"issue":"9","key":"15127_CR30","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early Triple-Negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"issue":"5","key":"15127_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with Early-Stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6650.","journal-title":"JAMA Oncol"},{"issue":"8","key":"15127_CR32","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, Gligorov J, Andr\u00e9 F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line Paclitaxel with or without Atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994\u20131004. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.801.","journal-title":"Ann Oncol"},{"issue":"4","key":"15127_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3.","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499\u2013511. https:\/\/doi.org\/10.1016\/S1470-2045(20)30754-3.","journal-title":"Lancet Oncol"},{"issue":"5","key":"15127_CR34","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without Atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33(5):534\u201343. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.004.","journal-title":"Ann Oncol"},{"issue":"12","key":"15127_CR35","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/s41591-022-02126-1","volume":"28","author":"AH R\u00f8ssevold","year":"2022","unstructured":"R\u00f8ssevold AH, Andresen NK, Bjerre CA, et al. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nat Med. 2022;28(12):2573\u201383. https:\/\/doi.org\/10.1038\/s41591-022-02126-1.","journal-title":"Nat Med"},{"issue":"1","key":"15127_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41523-022-00500-3","volume":"8","author":"FO Ademuyiwa","year":"2022","unstructured":"Ademuyiwa FO, Gao F, Street CR, et al. A randomized phase 2 study of neoadjuvant carboplatin and Paclitaxel with or without Atezolizumab in triple negative breast cancer (TNBC)-NCI 10013. NPJ Breast Cancer. 2022;8(1):134. https:\/\/doi.org\/10.1038\/s41523-022-00500-3.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"15127_CR37","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1038\/s41467-023-42744-y","volume":"14","author":"L Buisseret","year":"2023","unstructured":"Buisseret L, Loirat D, Aftimos P, et al. Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial. Nat Commun. 2023;14(1):7018. https:\/\/doi.org\/10.1038\/s41467-023-42744-y.","journal-title":"Nat Commun"},{"issue":"1","key":"15127_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","volume":"30","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Ouyang Q, Sun T, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024;30(1):249\u201356. https:\/\/doi.org\/10.1038\/s41591-023-02677-x.","journal-title":"Nat Med"},{"issue":"1","key":"15127_CR39","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1186\/s12885-021-08997-w","volume":"21","author":"Y Xin","year":"2021","unstructured":"Xin Y, Shen G, Zheng Y, et al. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21(1):1261. https:\/\/doi.org\/10.1186\/s12885-021-08997-w.","journal-title":"BMC Cancer"},{"issue":"24","key":"15127_CR40","doi-asserted-by":"publisher","first-page":"21873","DOI":"10.1002\/cam4.6760","volume":"12","author":"X Gao","year":"2023","unstructured":"Gao X, Zhu Y, Wang P, et al. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: A systematic review and meta-analysis. Cancer Med. 2023;12(24):21873\u201384. https:\/\/doi.org\/10.1002\/cam4.6760.","journal-title":"Cancer Med"},{"issue":"7\u20138","key":"15127_CR41","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.bulcan.2023.04.011","volume":"110","author":"C Gu\u00e9rin","year":"2023","unstructured":"Gu\u00e9rin C, Laramas M, Bettega F, et al. Safety profile of immune checkpoint inhibitors according to cancer type. Bull Cancer. 2023;110(7\u20138):825\u201335. https:\/\/doi.org\/10.1016\/j.bulcan.2023.04.011.","journal-title":"Bull Cancer"},{"issue":"5","key":"15127_CR42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00228-024-03647-z","volume":"80","author":"C Oliveira","year":"2024","unstructured":"Oliveira C, Mainoli B, Duarte GS, et al. Immune-related serious adverse events with immune checkpoint inhibitors: systematic review and network meta-analysis. Eur J Clin Pharmacol. 2024;80(5):677\u201384. https:\/\/doi.org\/10.1007\/s00228-024-03647-z.","journal-title":"Eur J Clin Pharmacol."},{"key":"15127_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/ITT.S141577","volume":"6","author":"M Davies","year":"2017","unstructured":"Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther. 2017;6:51\u201371. https:\/\/doi.org\/10.2147\/ITT.S141577.","journal-title":"Immunotargets Ther"},{"issue":"6","key":"15127_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00005-020-00601-6","volume":"68","author":"Y Yan","year":"2020","unstructured":"Yan Y, Zhang L, Zuo Y, et al. Immune checkpoint Blockade in cancer immunotherapy: Mechanisms, clinical Outcomes, and safety profiles of PD-1\/PD-L1 inhibitors. Arch Immunol Ther Exp (Warsz). 2020;68(6):36. https:\/\/doi.org\/10.1007\/s00005-020-00601-6.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"16","key":"15127_CR45","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.7150\/jca.87335","volume":"14","author":"AP Machado","year":"2023","unstructured":"Machado AP, Ratliff H, Abdelwahab A, et al. The safety of immunosuppressants used in the treatment of immune-Related adverse events due to immune checkpoint inhibitors: a systematic review. J Cancer. 2023;14(16):2956\u201363. https:\/\/doi.org\/10.7150\/jca.87335.","journal-title":"J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15127-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15127-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15127-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:16:00Z","timestamp":1764180960000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15127-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15127"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15127-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1804"}}